Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. (Q42914716)

From Wikidata
Jump to navigation Jump to search
scientific article published on 7 September 2010
edit
Language Label Description Also known as
English
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
scientific article published on 7 September 2010

    Statements

    title
    Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial (English)
    1 reference
    stated in
    Europe PubMed Central
    PubMed publication ID
    20823406
    reference URL
    https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20823406%20AND%20SRC:MED&resulttype=core&format=json
    retrieved
    13 February 2020
    author

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit
                      Retrieved from "https://www.wikidata.org/w/index.php?title=Q42914716&oldid=1858029293"